KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rigel Pharmaceuticals (RIGL) Enterprise Value: 2009-2025

Historic Enterprise Value for Rigel Pharmaceuticals (RIGL) over the last 16 years, with Sep 2025 value amounting to $371.0 million.

  • Rigel Pharmaceuticals' Enterprise Value rose 65.95% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.2 million, marking a year-over-year increase of 59.18%. This contributed to the annual value of $219.0 million for FY2024, which is 11.77% up from last year.
  • Rigel Pharmaceuticals' Enterprise Value amounted to $371.0 million in Q3 2025, which was up 63.90% from $226.4 million recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' Enterprise Value registered a high of $585.1 million during Q2 2021, and its lowest value of $95.1 million during Q2 2024.
  • Its 3-year average for Enterprise Value is $203.8 million, with a median of $210.0 million in 2024.
  • In the last 5 years, Rigel Pharmaceuticals' Enterprise Value spiked by 224.59% in 2021 and then slumped by 82.01% in 2022.
  • Quarterly analysis of 5 years shows Rigel Pharmaceuticals' Enterprise Value stood at $328.2 million in 2021, then plummeted by 38.74% to $201.0 million in 2022, then declined by 2.56% to $195.9 million in 2023, then increased by 11.77% to $219.0 million in 2024, then surged by 65.95% to $371.0 million in 2025.
  • Its Enterprise Value stands at $371.0 million for Q3 2025, versus $226.4 million for Q2 2025 and $244.3 million for Q1 2025.